Catalog No.	C057P.05
Product Name	Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg | C057P.05
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD20, MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human CD20 monoclonal antibody obinutuzumab biosimilar was produced in the obinutuzumab biosimilar CHO stable cell line.
Specificity/Sensitivity	The in vivo grade obinutuzumab biosimilar specifically binds to the human type II CD20 antibodies.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by obinutuzumab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 0.05 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Obinutuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C057P.05: Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab.

Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.

In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

Syd Labs also provides the following anti-CD20 antibody biosimilar proteins:
Rituximab Biosimilar, research grade, anti-human CD20 monoclonal antibody

Obinutuzumab Biosimilar from: Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg: C057P.05 Syd Labs

No more offers for this product!